CytoReason develops a cell-centered computational model of the human body designed to discover complex patterns in biological data.
CytoReason has raised $80.0M in total funding. The most recent round was Series B. The last funding was announced in July 2024.
CytoReason's investors include NVIDIA, Pfizer, Thermo Fisher Scientific, OurCrowd, Asymmetry Ventures.
CytoReason is headquartered in Tel Aviv, Israel.
CytoReason develops a cell-centered computational model of the human body designed to discover complex patterns in biological data.
CytoReason is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CytoReason — Funding & Investors." VCBacked, July 17, 2024, https://www.vcbacked.co/company/cytoreason. Accessed July 19, 2026.
VCBacked. (2024). CytoReason — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/cytoreason
{{cite web |title=CytoReason — Funding & Investors |url=https://www.vcbacked.co/company/cytoreason |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated